Premium
Glucocorticoids ameliorate arthritis through epigenetic regulation of CCL17 production
Author(s) -
Achuthan Adrian,
Lupancu Tanya,
Lee Ming-Chin,
Fleetwood Andrew,
Cook Andrew,
Hamilton John
Publication year - 2020
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.2020.34.s1.00656
Subject(s) - proinflammatory cytokine , ccl17 , immunology , medicine , arthritis , inflammation , rheumatoid arthritis , cancer research , chemokine , cxcl10
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease, which leads to poor quality of life due to the debilitating effect of inflammation. Clinical trials in rheumatoid arthritis targetting the cytokine, granulocyte macrophage‐colony stimulating factor (GM‐CSF) are showing promise although its mode of action remains largely unknown. We have previously shown that that GM‐CSF drives CCL17 production via a new interferon regulatory factor 4 (IRF4)‐dependent pathway in human monocytes and mouse macrophages, as well as in vivo. Importantly, in arthritis and pain models IRF4‐regulated CCL17 formation mediates the proinflammatory and algesic actions of GM‐CSF. Glucocorticoids (GCs) are potent anti‐inflammatory and immunosuppressive agents broadly used in anti‐inflammatory therapy, albeit with adverse side effects associated with long‐term usage. The negative consequences of GC therapy provide an impetus for research into gaining insights into the molecular mechanisms of GC action on immune cells. We report here that GM‐CSF‐induced CCL17 expression is inhibited by GCs in human monocytes and mouse macrophages. Moreover, we provide evidence for the first time that GCs suppress GM‐CSF‐induced IRF4 expression via regulating the expression and activity of JMJD3, which demethylases trimethylated‐H3K27. Further, we demonstrate that GCs suppress the expression of JMJD3, via the recruitment of GC receptor‐alpha to the negative GC response element in the upstream region of JMJD3 gene. Significantly, we measured elevated levels of CCL17 in synovial fluid from patients with RA compared to healthy controls. Using synovial fluid mononuclear cells from RA patients, we provide molecular evidence for the anti‐inflammatory actions of GCs through epigenetic regulation of IRF4 expression and downstream inhibition of CCL17 production. The delineated pathway potentially provides new therapeutic options for the treatment of inflammatory diseases and their associated pain. Support or Funding Information NHMRC Project Grant and Seeding Ideas Grant from the University of Melbourne